Latest news with #eBioMedicine
Emirates 24/7
4 hours ago
- Health
- Emirates 24/7
Study links 'forever chemicals' to increased risk of type 2 diabetes
Exposure to a class of synthetic chemicals known as per- and polyfluoroalkyl substances (PFAS), commonly referred to as "forever chemicals", may increase the risk of developing type 2 diabetes, according to a new study led by researchers at Mount Sinai. The findings were published in eBioMedicine. The team conducted a nested case-control study within BioMe, a large, electronic health record-linked research database comprising records of more than 70,000 study participants who have sought care at The Mount Sinai Hospital in New York City since 2007. Based on available data, the study analysed 180 people recently diagnosed with type 2 diabetes (T2D) and compared them to 180 similar individuals without diabetes. All participants were matched based on age, sex, and ancestry. Researchers used blood samples to analyse PFAS levels - a group of chemicals used in everything from nonstick cookware to stain-resistant furniture to waterproof clothing -and found that higher levels of PFAS were associated with a significantly greater risk of developing T2D in the future. Specifically, each increase in range of PFAS exposure was linked to a 31 percent increase in risk. The team also found that these associations could be due to metabolic irregularities in amino acid biosynthesis and drug metabolism, which may help explain how PFAS affect the body's ability to regulate blood sugar. Findings from this study underscore the importance of preventing PFAS exposures to promote public health and of advancing knowledge about potential mechanisms underlying the PFAS' impacts on human metabolism. Follow Emirates 24|7 on Google News.
Al Etihad
5 hours ago
- Health
- Al Etihad
'Forever Chemicals' linked to higher risk of Type 2 diabetes
23 July 2025 13:36 NEW YORK (ALETIHAD) Exposure to a class of synthetic chemicals known as per- and polyfluoroalkyl substances (PFAS)—often called 'forever chemicals'—may increase the risk of developing type 2 diabetes, according to a new study led by Mount Sinai researchers. The findings were published on Tuesday in eBioMedicine. The team conducted a nested case-control study - an observational study that is conducted within a larger cohort study - within BioMe, a large, electronic health record-linked research database comprising records of more than 70,000 study participants who have sought care at The Mount Sinai Hospital in New York City since 2007. Based on available data, the study analysed 180 people recently diagnosed with type 2 diabetes and compared them to 180 similar individuals without diabetes. Researchers used blood samples to analyse PFAS levels—a group of chemicals used in everything from nonstick cookware to stain-resistant furniture to waterproof clothing—and found that higher levels of PFAS were associated with a significantly greater risk of developing type 2 diabetes in the each increase in range of PFAS exposure was linked to a 31 percent increase in risk. The team also found that these associations could be due to metabolic irregularities in amino acid biosynthesis and drug metabolism, which may help explain how PFAS affect the body's ability to regulate blood sugar.'PFAS are synthetic chemicals that resist heat, oil, water, and stains, and are found in countless everyday consumer products,' said Vishal Midya, PhD, MStat, corresponding author and Assistant Professor, Environmental Medicine, Icahn School of Medicine at Mount Sinai.'Because they don't break down easily, PFAS accumulate in the environment—and in human bodies. Our study is one of the first to examine how these chemicals may disrupt the body's metabolism in ways that increase diabetes risk—particularly in diverse US populations.' Findings from this study underscore the importance of preventing PFAS exposures to promote public health and of advancing knowledge about potential mechanisms underlying the PFAS impacts on human metabolism. The researchers called for further research studies, integrating environmental with genetic data to better understand how environmental exposures interact with human metabolism and contribute to chronic disease. They also call for larger study populations, expanding over the life course, from preconception to elderly, to understand environmental health impacts across the lifespan and at vulnerable life periods. Source: Aletihad - Abu Dhabi
Time of India
a day ago
- Health
- Time of India
Using non-stick cookware at home? Here's why it could increase the risk of type 2 diabetes
A recent study by Mount Sinai researchers reveals a significant link between exposure to PFAS, commonly known as forever chemicals, and an increased risk of developing type 2 diabetes. Analyzing data from over 70,000 participants, the study found that higher PFAS levels correlate with a 31% increase in diabetes risk, potentially due to metabolic irregularities. Forever chemicals are everywhere. From the water we drink to the food we eat, and even in human cells, this class of synthetic chemicals is everywhere. But can they cause illnesses? A recent study has looked at the association between forever chemicals and type 2 diabetes. A new study led by Mount Sinai researchers found a close link between forever chemicals and diabetes. The findings are published in eBioMedicine . What are forever chemicals Forever chemicals, which were developed in the 1940s, have become a part of our lives now. Also known as PFAs, per- and polyfluoroalkyl substances, forever chemicals, are a class of synthetic chemicals. Known for their durability (resistance to heat, oil, and water), PFAs are used in products ranging from Teflon pans to cosmetics, dental floss, and fast-food wrappers. Yes, from nonstick cookware to stain-resistant furniture to waterproof clothing, PFAs are everywhere PFAs and type 2 diabetes The researchers have now found a link between PFAs and type 2 diabetes. They found that exposure to these chemicals may increase the risk of developing type 2 diabetes. They found that these associations could be due to metabolic irregularities in amino acid biosynthesis and drug metabolism, which may help explain how PFAS affect the body's ability to regulate blood sugar. To understand the impact of PFAs on human health, the researchers conducted a study. They looked at the data of more than 70,000 study participants who have sought care at The Mount Sinai Hospital in New York City since 2007. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like If you have a mouse, play this game for 1 minute Navy Quest Undo by Taboola by Taboola Based on available data, the researchers analyzed 180 people recently diagnosed with type 2 diabetes (T2D) and compared them to 180 similar individuals without diabetes. The researchers then looked at their blood samples to analyze PFAS levels. They found that higher levels of PFAS were associated with a significantly greater risk of developing T2D in the future. Each increase in range of PFAS exposure was linked to a 31% increase in risk. They also found that these associations could be due to metabolic irregularities in amino acid biosynthesis and drug metabolism, which may help explain how PFAS affect the body's ability to regulate blood sugar. What are the experts saying Vishal Midya, PhD, MStat, corresponding author and assistant Professor, Environmental Medicine, Icahn School of Medicine at Mount Sinai, said, 'PFAS are synthetic chemicals that resist heat, oil, water, and stains, and are found in countless everyday consumer products. Because they don't break down easily, PFAS accumulate in the environment—and in human bodies. Our study is one of the first to examine how these chemicals may disrupt the body's metabolism in ways that increase diabetes risk—particularly in diverse US populations. ' Supreme Court Pushes Central Govt to Finalise FOPL: What It Means & Why It Matters? | Explained The study emphasizes the importance of preventing PFAS exposures to promote public health. 'This research leverages an exposomics framework to characterize environmental impacts and associated metabolic alterations contributing to the development of type 2 diabetes in vulnerable US populations. Findings can help us design more effective interventions for the early prevention of type 2 diabetes in the future, taking into account individuals' exposures to environmental chemicals along with other well-known genetic, clinical, and lifestyle factors implicated in diabetes development. Mounting research suggests that PFAS are a risk factor for several chronic diseases, such as obesity, liver disease, and diabetes,' Damaskini Valvi, MD, PhD, MPH, senior author and associate professor, Public Health and Environmental Medicine, Icahn School of Medicine at Mount Sinai, added.
Yahoo
5 days ago
- Health
- Yahoo
New test could revolutionise aftercare for thousands of breast cancer patients
Scientists have developed a new test for certain breast cancer patients which can predict whether or not their cancer is likely to return just two weeks after they start treatment. Experts said thousands of breast cancer patients could be spared unnecessary treatment as a result. The new test has been devised to detect the likelihood of cancer reoccurring in patients with a type of breast cancer known as oestrogen receptor positive, human epidermal growth factor receptor 2 positive – which accounts for around 200,000 cases of cancer each year around the globe. Writing in the journal eBioMedicine, experts said the test means that some patients will be able to 'de-escalate' their treatment while it could also help identify those who need 'more intensive therapeutic strategies'. The test, which was developed by scientists at The Institute for Cancer Research, London, correctly identifies the 6% of patients at highest risk of relapse. Researchers analysed tumour samples from 213 patients. They found that two weeks of hormone therapy changes the characteristics of some tumours, causing them to shift their subtype. The patients with the highest risk of cancer returning had a type of tumour called Luminal B that did not change after this short-term hormone therapy. Experts said these patients will require more intensive treatment. This is your breast check reminder! Learn the signs and symptoms of breast — Breast Cancer Now (@BreastCancerNow) May 6, 2025 They said the findings highlight the benefit of two weeks of hormone therapy before surgery to help guide doctors' decision making. Corresponding author of the study, Dr Maggie Cheang, from The Institute of Cancer Research, London, said: 'To deliver truly personalised care, we need to refine how we classify breast cancer, so that each patient receives the treatment most likely to benefit them. 'While current classification relies on hormone receptor and HER2 status, we know that patients within these groups can respond very differently to the same therapy. 'Our earlier research identified distinct molecular subtypes within HER2-positive, oestrogen receptor-positive breast cancer. In this new study, we've shown that these subtypes can shift after just two weeks of hormone therapy. 'This insight helps us identify which patients are likely to respond well and which may show early signs of treatment resistance, offering the opportunity to tailor treatment strategies sooner. 'Ultimately, our findings move us closer to more precise, patient-centred care for this overlooked breast cancer subtype.' Professor Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'By decoding the underlying biology of tumours, we can tailor treatments to individual patients.' Dr Simon Vincent, chief scientific officer at Breast Cancer Now, which part-funded the study, said: 'These findings add to the growing evidence that genomic testing can play a powerful role in helping to predict the risk of a woman's breast cancer coming back, particularly in people with ER-positive, HER2-positive breast cancer. 'There's potential for women to benefit hugely from this research in the future, with it ensuring they avoid undergoing unnecessary treatment and leading to more personalised treatment plans, so that women receive the most effective therapy for their specific type of breast cancer.'
The Independent
5 days ago
- Health
- The Independent
Breast cancer breakthrough as new test could revolutionise treatment
A new test for breast cancer patients has been developed which can predict whether or not their cancer is likely to return just two weeks after they start treatment. Experts said thousands of breast cancer patients could be spared unnecessary treatment as a result. The new test has been devised by scientists to detect the likelihood of cancer reoccurring in patients with a type of breast cancer known as oestrogen receptor positive, human epidermal growth factor receptor 2 positive – which accounts for around 200,000 cases of cancer each year around the globe. Writing in the journal eBioMedicine, experts said the test means that some patients will be able to 'de-escalate' their treatment while it could also help identify those who need 'more intensive therapeutic strategies'. The test, which was developed by scientists at The Institute for Cancer Research, London, correctly identifies the 6% of patients at highest risk of relapse. Researchers analysed tumour samples from 213 patients. They found that two weeks of hormone therapy changes the characteristics of some tumours, causing them to shift their subtype. The patients with the highest risk of cancer returning had a type of tumour called Luminal B that did not change after this short-term hormone therapy. Experts said these patients will require more intensive treatment. They said the findings highlight the benefit of two weeks of hormone therapy before surgery to help guide doctors' decision making. Corresponding author of the study, Dr Maggie Cheang, from The Institute of Cancer Research, London, said: 'To deliver truly personalised care, we need to refine how we classify breast cancer, so that each patient receives the treatment most likely to benefit them. 'While current classification relies on hormone receptor and HER2 status, we know that patients within these groups can respond very differently to the same therapy. 'Our earlier research identified distinct molecular subtypes within HER2-positive, oestrogen receptor-positive breast cancer. In this new study, we've shown that these subtypes can shift after just two weeks of hormone therapy. 'This insight helps us identify which patients are likely to respond well and which may show early signs of treatment resistance, offering the opportunity to tailor treatment strategies sooner. 'Ultimately, our findings move us closer to more precise, patient-centred care for this overlooked breast cancer subtype.' Professor Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'By decoding the underlying biology of tumours, we can tailor treatments to individual patients.' Dr Simon Vincent, chief scientific officer at Breast Cancer Now, which part-funded the study, said: 'These findings add to the growing evidence that genomic testing can play a powerful role in helping to predict the risk of a woman's breast cancer coming back, particularly in people with ER-positive, HER2-positive breast cancer. 'There's potential for women to benefit hugely from this research in the future, with it ensuring they avoid undergoing unnecessary treatment and leading to more personalised treatment plans, so that women receive the most effective therapy for their specific type of breast cancer.'
